NSE: LALPATHLAB | BSE: 539524

Expensive Performer

Download real time

2811.70 -99.50 (-3.42%)

27.73% Gain from 52W Low

486.5K NSE+BSE Volume

NSE 28 Apr, 2025 3:31 PM (IST)

23,503.5

Market Cap

Market Runner Up

0.5

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd.

09 Nov 2022

2811.70

-3.42%

Margins improve despite slow growth

Accumulate: Dr. Lal Pathlabs Ltd.

ICICI Securities Limited

Dr Lal Pathlabs’ (Dr Lal) Q2FY23 performance was a mixed bag with slower-than-
expected growth in non-covid patient volumes, but healthy improvement in margins.

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2752.7

Dr. Lal Pathlabs Ltd.

10 Aug 2022

2811.70

-3.42%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. has an average target of 2898.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

16 Feb 2022

2811.70

-3.42%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal PathLabs Limited (DLPL) provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal Pathlabs Ltd. has an average target of 2898.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

05 Aug 2021

2811.70

-3.42%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic. Leveraging its dedicated network driven infrastructure and techenabled processes, we expect the company to be able to perform well in the expected third wave situation. Hence, we upgrade our rating on the...

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2752.7

Dr. Lal Pathlabs Ltd.

03 Aug 2021

2811.70

-3.42%

Company Update - Valuation running way ahead of fundamentals - SELL

Sell: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

unsustainable rise in volume of patients and samples (all time high) We reinitiate coverage on DLPL stock with Sell' rating, previously kept Under Review'. 1QFY22 earnings were higher than our estimates solely driven by additional volumes, due to large number of patients in the second wave. Business in core portfolio grew 15% YoY given 1) all collection centers and labs resumed operations much earlier than expected 2) high revenue...

Dr. Lal Pathlabs Ltd. has an average target of 2898.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

25 May 2021

2811.70

-3.42%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2752.7

Dr. Lal Pathlabs Ltd.

04 Feb 2021

2811.70

-3.42%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Company has 216 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal Pathlabs Ltd. has an average target of 2898.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

06 Aug 2020

2811.70

-3.42%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

The company's growth in COVID business, strong brand recall, gradual unlock of cities should support growth in upcoming quarters. Given the limited upside potential we downgrade our rating to HOLD with a revised target price of Rs. 1,995 based on 53x FY22E EPS. COVID-19 tests contribute to the top line DLPL's Q1FY21 top line went down 20.6% YoY to Rs. 266cr severely impacted by COVID-19 and subsequent lock down impacting the revenue in April (-61% YoY) and May (-12% YoY), however some respite was seen in June (+14% YoY) when cities were...

Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2905.2

Dr. Lal Pathlabs Ltd.

03 Aug 2020

2811.70

-3.42%

Q1FY21 Result Update - COVID test paper covers the cracks of slowdown - SELL

Sell: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

We remain negative on the entire diagnostic chain with a belief of 1) premium players losing their market share to unorganized players, 2) B2B (40% of revenue) partners negotiating to partially offset their loss of profit, 3) Inability to hike prices causing lower realization level (Revenue/Patient) and 4) higher fixed costs (60-65% of operating cost for DLPL), new compliance expense and home collection of samples will lead to lower EBITDA margin. However even after increased estimate, we maintain SELL' recommendation but revised TP to Rs1,006 (from Rs895) on PE 40x of FY22E due to challenging...

Dr. Lal Pathlabs Ltd. has an average target of 2898.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

19 May 2020

2811.70

-3.42%

Q4FY20 Result Update - Core biz recovery unlikely in near term; Downgrade to Sell

Sell: Dr. Lal Pathlabs Ltd.

Recommendation Target

Prabhudas Lilladhar

28-30% of revenue compared to last year in Q1FY21E and gradual recovery from Q2FY21E. As per the management, 60-65% of DLPL's total operating cost is fixed in nature and the new additional expense (cost of safety for...

Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2905.2

Is Dr. Lal Pathlabs Ltd. worth buying?

221 Votes:

Buy 75.57%

Sell 14.93%

Hold 9.5%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf